Tempus AI has acquired Personalis, Inc., a company specializing in advanced cancer diagnostics and personalized testing, for an undisclosed amount. This corporate acquisition sees Tempus AI integrating Personalis's innovative genomic profiling capabilities into its operations, marking a significant expansion in its healthcare technology portfolio. The transaction represents a direct purchase of Personalis by Tempus AI, not a funding round.
Personalis, based in Fremont, California, is dedicated to transforming cancer management through breakthrough personalized testing. The company's highly sensitive assays combine tumor-and-normal profiling with proprietary algorithms to deliver advanced insights into cancer evolution. Its products are designed to detect minimal residual disease (MRD) and recurrence at the earliest timepoints, enable the selection of targeted therapies based on ultra-comprehensive genomic profiling, and enhance biomarker strategy for drug development. Personalis aims to guide cancer care from initial biopsy through the patient's life.
The acquisition is strategically significant for Tempus AI, which stands to gain Personalis's deep expertise and established technologies in precision oncology. By incorporating Personalis's advanced genomic assays and analytical tools, Tempus AI can bolster its offerings in AI-driven healthcare and data analytics, particularly within the complex field of cancer. This move is expected to enhance Tempus AI's ability to provide comprehensive solutions for cancer diagnosis, monitoring, and treatment selection.
Expected synergies include the integration of Personalis's sophisticated genomic data with Tempus AI's artificial intelligence platform, potentially accelerating the discovery of new biomarkers and therapeutic targets. The combined entity aims to deliver more precise and actionable insights to clinicians and researchers, ultimately improving patient outcomes. This acquisition positions the unified company to drive further innovation in personalized cancer care and drug development.